Treasury Evaluates Outbound Investment Curbs on Chinese Biotech Over Dual-Use Risks
Treasury is examining outbound investment limits on Chinese biotech to address national security concerns around dual-use technologies. The move could affect venture funding, joint ventures, and technology licensing deals valued in the billions. Industry groups warn of slowed innovation and retaliatory measures from Beijing.
Discussions center on expanding the 2023 executive order on outbound investment screening, which currently prioritizes semiconductors, AI, and quantum computing. Biotech has emerged as a candidate sector because certain platforms enable pathogen engineering or advanced therapeutics with clear defense implications. Internal reviews reference classified assessments of Chinese military-civil fusion programs that integrate commercial gene-editing firms with PLA research institutes.
Treasury Department: Draft rules covering at least three biotech subsectors published in Federal Register within nine months if current administration retains office.
Sources (3)
- [1]Primary Source(https://www.statnews.com/2026/10/22/biotech-news-treasury-restrictions-for-us-investment-in-chinese-biotech/)
- [2]Supporting Source(https://home.treasury.gov/policy-issues/international/outbound-investment-review)
- [3]Supporting Source(https://www.reuters.com/world/us/us-weighs-new-rules-chinese-biotech-investment-2024-09-15/)